Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic trial highlights effectiveness of Reveal XT

Medtronic trial highlights effectiveness of Reveal XT

9th May 2011

Medtronic has published data from a new clinical study that illustrates the effectiveness of its Reveal XT cardiac monitor in tracking the progression of atrial fibrillation (AF).

The Discern AF trial was supported by the medical technology firm and was designed to assess the incidence of symptomatic and asymptomatic AF episodes in patients before and after undergoing radiofrequency ablation.

Monitoring of patients was performed using Medtronic's implantable device, with results revealing that observation of symptoms alone can lead to an underestimation of overall disease burden post-ablation.

Pat Mackin, president of the cardiac rhythm disease management business and senior vice-president at Medtronic, said this trial shows the benefits Reveal XT can provide in guiding AF care.

"Medtronic is committed to developing leading medical technologies to treat and manage cardiac rhythm diseases such as AF and new research such as Discern AF is a cornerstone to guide our development strategies," he added.

This comes in the same month that another Medtronic study showed that cardiac resynchronisation therapy can offer an effective treatment option for AF patients.ADNFCR-8000103-ID-800524215-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.